Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

956 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Acetylsalicylic Acid in Fixed-Dose Combination with Clopidogrel Versus Enteric Aspirin in Chinese Subjects Under Fasting Conditions: A Phase 1, Open-Label, Randomized, Crossover Study.
Wang L, Di Y, Guo T, Ming JE, Kong F, Yin H, Zhang L, Xie F, Yang N, Ping C, Li Y, Hou J. Wang L, et al. Among authors: di y. Adv Ther. 2020 Jun;37(6):2696-2709. doi: 10.1007/s12325-020-01369-z. Epub 2020 May 16. Adv Ther. 2020. PMID: 32418143 Free PMC article. Clinical Trial.
The similarity of pharmacokinetics, pharmacodynamics, safety, and immunogenicity between recombinant fully human anti-RANKL monoclonal antibody injection (MW032) and denosumab (Xgeva®) in healthy Chinese subjects: A single-center, randomized, double-blind, single-dose, parallel-controlled clinical study.
Hou J, Hu Z, Xu W, Di Y, Song C, Wu F, Liu J, Guo Y. Hou J, et al. Among authors: di y. Int Immunopharmacol. 2022 Jun;107:108666. doi: 10.1016/j.intimp.2022.108666. Epub 2022 Mar 12. Int Immunopharmacol. 2022. PMID: 35286913 Clinical Trial.
Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomized, double-blind, single-dose, parallel-controlled trial.
Guo Y, Guo T, Di Y, Xu W, Hu Z, Xiao Y, Yu H, Hou J. Guo Y, et al. Among authors: di y. Expert Opin Biol Ther. 2023 Jul-Dec;23(8):705-715. doi: 10.1080/14712598.2023.2178298. Epub 2023 Mar 9. Expert Opin Biol Ther. 2023. PMID: 36892190 Clinical Trial.
956 results